Does Long-Term Aspirin Reduce Stroke Risk Overall?
Long-term low-dose aspirin (typically 75-325 mg daily) lowers the risk of ischemic stroke by about 20-25% in people with prior cardiovascular events or high risk factors, such as atrial fibrillation or diabetes.[1][2] It inhibits platelet aggregation, preventing blood clots that cause most strokes. A meta-analysis of 16 trials with over 17,000 participants showed aspirin reduced nonfatal stroke by 22% without increasing overall mortality.[3] Guidelines from the American Heart Association recommend it for secondary prevention after a stroke or TIA, cutting recurrence risk by 13-20%.[1]
Why Doesn't It Help—or Could Hurt—Healthy People?
In primary prevention (no prior events), benefits are smaller and risks often outweigh them. The ASPREE trial (19,000+ older adults) found no reduction in stroke risk over 5 years, but a 38% increase in major hemorrhages.[4] USPSTF advises against routine use in adults 60+ due to bleeding risks; for ages 40-59 with 10-year CVD risk ≥10%, it may offer net benefit but requires individualized assessment.[5] Overall stroke risk drops modestly (6-12%) but intracranial bleeds rise 30-50%.[2]
What Types of Strokes Are Affected?
- Ischemic strokes (clot-based, 85% of cases): Risk decreases 18-25% with long-term use in at-risk groups.[3]
- Hemorrhagic strokes (bleeding): Risk increases 30-70%, especially at higher doses or with factors like hypertension or alcohol use.[2][6] Net effect: No change or slight increase in total stroke incidence in low-risk populations.[4]
What Are the Main Risks and Bleeding Concerns?
Gastrointestinal bleeding doubles (2-4 extra events per 1,000 person-years), with 1-2% annual risk.[1][5] Intracranial hemorrhage risk rises from 0.1% to 0.3% yearly.[6] Long-term use (>5 years) amplifies this, particularly in those over 70 or on anticoagulants. Women face higher GI bleed risk than men.[2]
Who Should—or Shouldn't—Take It Long-Term?
Recommended for:
- Secondary prevention post-ischemic stroke/TIA (81 mg daily).[1]
- High-risk patients (e.g., diabetes + CVD history).[5]
Avoid or reconsider:
- Low-risk adults without CVD history.
- Age 60+ without prior events.
- Bleeding disorders, peptic ulcers, or concurrent NSAIDs/steroids.[1][5]
Consult a doctor; alternatives like clopidogrel may suit some.
How Do Recent Guidelines and Studies Compare?
| Guideline/Study | Population | Stroke Risk Change | Key Caveat |
|-----------------|------------|---------------------|------------|
| AHA/ASA 2021[1] | Secondary prevention | ↓13-20% ischemic | ↑ Hemorrhage |
| USPSTF 2022[5] | Primary, 40-59 high-risk | Net benefit possible | Weigh bleeds |
| ASPREE 2018[4] | Healthy 70+ | No change total | ↑ Hemorrhage 38% |
| ARRIVE 2018[7] | Moderate-risk adults | No significant reduction | GI bleeds ↑ |
Trends show shift away from broad primary use since 2016-2022 trials.
[1]: AHA/ASA Stroke Guidelines
[2]: Antithrombotic Trialists' Collaboration Meta-Analysis
[3]: BMJ Aspirin Review
[4]: ASPREE Trial (NEJM)
[5]: USPSTF Aspirin Recommendation
[6]: Lancet Hemorrhagic Risk Review
[7]: ARRIVE Trial (Lancet)